Adar1 Capital Management, Llc Buys 292,850 Shares of NextCure (NASDAQ:NXTC) Stock

NextCure, Inc. (NASDAQ:NXTC) major shareholder Adar1 Capital Management, Llc bought 292,850 shares of the business’s stock in a transaction on Thursday, July 30th. The shares were acquired at an average price of $4.93 per share, with a total value of $1,443,750.50. Following the completion of the purchase, the insider directly owned 686,116 shares of the company’s stock, valued at approximately $3,382,551.88. The trade was a 74.47% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Friday, July 31st, Adar1 Capital Management, Llc purchased 36,303 shares of NextCure stock. The stock was acquired at an average price of $4.94 per share, for a total transaction of $179,336.82.
• On Wednesday, July 29th, Adar1 Capital Management, Llc purchased 3,410 shares of NextCure stock. The stock was acquired at an average price of $5.00 per share, for a total transaction of $17,050.00.
• On Tuesday, July 28th, Adar1 Capital Management, Llc purchased 6,400 shares of NextCure stock. The shares were acquired at an average cost of $4.95 per share, with a total value of $31,680.00.
• On Monday, July 27th, Adar1 Capital Management, Llc acquired 7,798 shares of NextCure stock. The shares were acquired at an average price of $5.00 per share, with a total value of $38,990.00.

NextCure Stock Up 31.4%

NASDAQ:NXTC opened at $5.78 on Wednesday. The stock’s 50-day simple moving average is $3.39 and its 200 day simple moving average is $8.54. The firm has a market capitalization of $20.87 million, a PE ratio of -0.34 and a beta of 1.27. NextCure, Inc. has a twelve month low of $1.55 and a twelve month high of $15.74.

NextCure (NASDAQ:NXTC) last released its earnings results on Thursday, May 7th. The company reported ($1.87) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.10) by $0.23. On average, analysts anticipate that NextCure, Inc. will post -7.89 EPS for the current fiscal year.

Institutional Investors Weigh In On NextCure

Hedge funds have recently added to or reduced their stakes in the business. Marshall Wace LLP acquired a new position in NextCure in the 4th quarter valued at approximately $160,000. Millennium Management LLC acquired a new stake in NextCure in the fourth quarter valued at $185,000. Geode Capital Management LLC increased its holdings in NextCure by 18.6% in the fourth quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock valued at $329,000 after purchasing an additional 3,636 shares during the period. Cable Car Capital LP raised its position in NextCure by 13.1% during the 2nd quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock worth $349,000 after purchasing an additional 88,040 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in NextCure by 18.7% during the 4th quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock worth $477,000 after buying an additional 5,300 shares during the period. 42.65% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently commented on NXTC shares. Weiss Ratings downgraded shares of NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 7th. Wall Street Zen downgraded shares of NextCure from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of NextCure in a report on Wednesday, July 15th. Finally, Zacks Research upgraded NextCure from a “strong sell” rating to a “hold” rating in a research note on Thursday, June 11th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $19.00.

NextCure Company Profile

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.